A randomized, double-blind, placebo-controlled study of safety and efficacy of CORLUX (mifepristone) in the treatment of psychotic symptoms in patients with major depressive disorder with psychotic features.

Trial Profile

A randomized, double-blind, placebo-controlled study of safety and efficacy of CORLUX (mifepristone) in the treatment of psychotic symptoms in patients with major depressive disorder with psychotic features.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 1460) assessing incidence of adrenal insufficiency with normal cortisol levels presented at The 98th Annual Meeting of the Endocrine Society.
    • 14 Feb 2012 Actual patient number is 257 according to ClinicalTrials.gov.
    • 14 Feb 2012 Actual patient number is 257 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top